Immunovant (IMVT) Income from Continuing Operations (2018 - 2026)
Immunovant's Income from Continuing Operations was -$153.22 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$120.61 million a year earlier.
Powered by 
Analysis
Immunovant (IMVT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
On a trailing twelve-month basis, Immunovant's Income from Continuing Operations was -$538.22 million through Jun 30, 2026; for FY2026 (ended Mar 31, 2026), it came in at -$505.61 million.
- In earlier fiscal years, Income from Continuing Operations was -$413.84 million in FY2025, -$259.34 million in FY2024, -$210.96 million in FY2023 and -$156.73 million in FY2022.
- The fiscal Q1 2027 figure marks the lowest quarterly Income from Continuing Operations in data going back to fiscal Q3 2019.
- Per Business Quant data, IMVT's Income from Continuing Operations in the three fiscal quarters before Q1 2027 was -$147.86 million (Q4 2026), -$110.64 million (Q3 2026) and -$126.5 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Immunovant | 6.97 Bn | 6.97 Bn | - | -153.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -153.22 Mn |
| Mar 31, 2026 | -147.86 Mn |
| Dec 31, 2025 | -110.64 Mn |
| Sep 30, 2025 | -126.50 Mn |
| Jun 30, 2025 | -120.61 Mn |
| Mar 31, 2025 | -106.45 Mn |
| Dec 31, 2024 | -111.12 Mn |
| Sep 30, 2024 | -109.12 Mn |
| Jun 30, 2024 | -87.15 Mn |
| Mar 31, 2024 | -75.32 Mn |
| Dec 31, 2023 | -51.42 Mn |
| Sep 30, 2023 | -58.66 Mn |
| Jun 30, 2023 | -73.94 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -63.23 Mn |
| Sep 30, 2022 | -47.93 Mn |
| Jun 30, 2022 | -40.37 Mn |
| Mar 31, 2022 | -47.17 Mn |
| Dec 31, 2021 | -41.39 Mn |
| Sep 30, 2021 | -37.70 Mn |
API Access
Immunovant Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=IMVT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "IMVT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=IMVT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();